Business Wire

JSR Life Sciences Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead KBI Biopharma and Selexis SA

Share

JSR Life Sciences, LLC (JSR) today announced that Mark W. Womack will serve as the Chief Executive Officer of two of its affiliate companies: KBI Biopharma, a leading global CDMO specializing in drug development and biologics manufacturing, and Selexis SA, an industry-leading cell line development provider. Womack will be responsible for the strategic vision, continued growth, and organizational culture of both organizations, which currently includes eight facilities in Europe and the U.S. Womack’s appointment is effective May 2, 2022. He will report to JSR Life Sciences President Tim Lowery.

“Mark’s impressive track record includes extensive CDMO and biologics experience, as well as the ability to deliver overall growth, revenue generation, and organizational alignment,” said Tim Lowery, President, JSR Life Sciences. “His innate commitment to quality and innovation is a natural fit for the JSR family and a significant win for Selexis and KBI partners and employees. I look forward to working with Mark and his teams as we continue to provide best-in-class capabilities for outsourced drug development and manufacturing services.”

Womack brings a consistent track record of successful leadership and life sciences experience to KBI and Selexis. He most recently served as the CEO and Managing Director of Stelis Biopharma, where he oversaw the development and implementation of the infrastructure for a pure-play CDMO, including an end-to-end biologics offering, across multiple facilities. In 2021, he led the company’s efforts to build and qualify a state-of-the-art vaccine facility capable of clinical and commercial-scale manufacturing in record time.

Prior to Stelis, Womack served as the Chief Business Officer at AGC Biologics, in which his extensive experience driving organizational performance improvements led to a nearly 300% increase in new sales in just two years. His career began with more than ten years of distinguished service in the U.S. Navy, where he was recognized with many of their highest honors for exceptional leadership.

“KBI and Selexis are helping create a world where everyone has access to vital treatments that improve or extend their lives,” said Womack. “I’m honored to join JSR and these two great organizations in their mission to help our clients solve their greatest scientific challenges – in turn, providing life-saving therapeutics to patients across the globe. I look forward to supporting the KBI and Selexis teams’ continued growth trajectory and building on their long commitment to quality and innovation.”

Womack joins KBI and Selexis amid a period of profound expansion for both companies. In April, KBI cut the ribbon on its new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina. This will soon be followed by significant European expansion through the opening of a newly scaled, state-of-the-art GMP facility that will co-locate both KBI Biopharma and Selexis SA in Geneva, Switzerland.

About JSR Life Sciences, LLC

A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR LS provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR LS offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR LS’s global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com

About KBI Biopharma

KBI Biopharma, a JSR Life Sciences company, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and beyond. KBI serves its global partners with multiple locations in Europe and the USA. www.kbibiopharma.com.

About Selexis SA

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 155 drug candidates in preclinical and clinical development and the manufacture of nine commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Missy Bindseil
JSR Life Sciences Company Inquiries
Director, Marketing & Communications
mbindseil@jsr-nahq.com

Laura Morgan
JSR Life Sciences Media Inquiries
Sam Brown Inc.
lauramorgan@sambrown.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chery Automobile - How It Flourishes on a Global Stage17.5.2022 11:00:00 EEST | Press release

What makes Chery outstanding in the increasingly competitive automobile market and becoming the leader of Chinese automobiles. The excellent technology, the inclusive and open pattern makes this question worth exploring. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005093/en/ (Photo: Business Wire) Obsessed with technology research and development Since its establishment more than 20 years ago, Chery has always adhered to technological innovations and mastered core technologies. A global automobile R&D team with more than 5,500 people has been established, and a complete technology and product R&D system has been formed, and a series of flagship models such as the TIGGO and OMODA have been built. The cumulative global sales volume has exceeded 10 million units. Twenty years of technical advancements With more than 20 years of independent innovation, a new R&D system and integrated platform for new energy vehicles has

Temenos Launches the CEO Navigator, a Data-Driven Value Advisory Service for Bank Executives17.5.2022 10:30:00 EEST | Press release

Temenos (SIX: TEMN) today launched Temenos CEO Navigator, a subscription-based customer value benchmarking and advisory service that gives C-level banking executives unique insights on how to optimize their technology investments to drive business value. The consultative, survey-based strategic service enables banks to discover the drivers of performance and value creation, and provides the business and IT metrics they need to track and improve profitability. It is built on Temenos’ proprietary value benchmark program with over 100 participating retail, corporate and private banks from across the world. The CEO Navigator uses over 50,000 data points on financial and operational metrics as well as qualitative best practices across the entire banking value chain irrespective of what solutions the bank runs, to provide banking leaders exclusive insights and Temenos industry know-how. They can assess how specific banking best practices and solution capabilities drive high performance in te

Thales Signs an Agreement with Sonae Investment Management to Acquire S21sec and Excellium, Reinforcing Its Cybersecurity Activities17.5.2022 10:26:00 EEST | Press release

Thales (Euronext Paris: HO) announces today the signature of a definitive agreement with Sonae Investment Management to acquire two of European leading cybersecurity companies, S21sec and Excellium, gathered under the holding company Maxive Cybersecurity. This acquisition will complement Thales’ cybersecurity portfolio, strengthening its incident detection and response services (Security Operations Centre – SOC) as well as consulting, audit and integration services. It will bring an extensive industrial expertise and a solid, diversified customer base of industrial companies and critical infrastructure providers, including in the financial services, government and public services, which accounted for more than 50% of its revenue in 2021. With 75% of staff at 9 sites in Spain and Portugal, and 25% in Luxembourg and Belgium, it will also materially expand Thales’s European cybersecurity footprint, building on the companies’ strong history of innovation and leadership in cybersecurity. Wi

Aqara Launches Amazon Brand Stores in Italy and Spain17.5.2022 10:00:00 EEST | Press release

Aqara, a leading provider of smart home products, announced the debut of its brand stores on Amazon.it and Amazon.es. Since the launch of Aqara’s first European brand store on Amazon UK in July 2021, the smart home manufacturer has expanded its Amazon presence to France, Germany, Italy and Spain, making the comprehensive portfolio of Aqara products easily accessible for smart home users across Europe. Aqara has been selling in Italy and Spain on the Apple Online Store and via local retailers, and the brand has become increasingly popular among the local users for the build quality, the accessible prices and the wide compatibility with major ecosystems including HomeKit, Alexa, and Google Home. The launch of its Amazon brand stores will bring more Aqara products to the local markets, ranging from smart home hubs, smart sensors, security cameras, wired and wireless switches, to smart shade controllers. The product lineup of the Aqara brand stores on Amazon.it and Amazon.es include: Camer

BearingPoint Study: Does Your Data Underpin Resilience or Undermine It?17.5.2022 09:55:00 EEST | Press release

Management and technology consultancy BearingPoint has created a deep dive study on enterprise data resilience. This paper is the first of five companion pieces to the 2021 ‘Can you thrive under pressure’ study, the analysis of over 5,000 projects leading to the ranking of 150 best practice resilient organizations. BearingPoint has also created a resilience benchmarking tool that enables any organization to assess their own alignment with the five fundamental pillars of resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005860/en/ BearingPoint Study: Does your data underpin resilience or undermine it? Key results at a glance. BearingPoint believe data and analytic resilience is undermined by lack of people empowerment, as 65% of organizations lack data literacy and 56% face cultural resistance to change. Other obstacles impacting data led change initiatives included lack of resources and funding (33%) and disco

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom